A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse

NCT02330991 | Completed Phase 2

• 1 other identifier: 2014062501
• Study Type: interventional
• Target: 204
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to evaluate the clinical benefit and safety of two different Dose-Intense temozolomide regimens（one-week on/one-week off regimen versus continuous dose-intense regimen）in patients with glioblastoma at first relapse.

Conditions

Glioblastoma

Keywords

glioblastoma; relapse; Temozolomide; glioblastoma at first relapse

Outcome Measures

Primary Outcomes (1)

• Progress-Free Survival at 6 months (PFS6)

  6 months

Secondary Outcomes (4)

• Overall Survival(OS)

  2 years

• Progression free survival

  2 years

• Objective Response Rate

  up to 52 weeks

• Number of Participants with Adverse Events as a Measure of Safety and Tolerability

  up to 52 weeks

Study Arms (2)

Arm1 ,one-week on/one-week off regimen

EXPERIMENTAL

One-week on/one-week off regimen is administered for 12 cycles of 28 days. Arm 1 receives temozolomide 150 mg/m2 daily during days 1 to 7 and 15 to 21 of each cycle.Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.

Drug: Temozolomide

Arm 2,continuous dose-intense regimen

EXPERIMENTAL

Continuous dose-intense regimen is administered for 12 cycles of 28 days .Arm 2 receives temozolomide 50mg/m2 daily during days 1 to 28 of each cycle. Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.

Drug: Temozolomide

Interventions

Temozolomide DRUG

Also known as: Temodal

Arm 2,continuous dose-intense regimen; Arm1 ,one-week on/one-week off regimen

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants must have histopathologically-confirmed, supratentorial, glioblastoma.
• Participants must have received first-line treatment regimen consisting of RT plus concomitant temozolomide followed by adjuvant temozolomide.
• Participants must be first recurrence or progression of glioblastoma after first-line treatment regimen.
• Participants must have demonstration of recurrent disease on MRI following prior therapy.
• Participants must have bi-dimensionally measurable disease with a minimum measurement of 1 cm in one dimension on MRI performed within 14 days prior to first treatment. If receiving corticosteroids, participants must be on a stable or decreasing dose of corticosteroids for at least 5 days prior to baseline MRI.
• Participants must have developed progressive disease after receiving prior therapy and must have an interval of at least 12 weeks from the completion of radiation and concomitant temozolomide therapy to study entry (unless progressive tumor growth is outside the radiation field or there is histopathological confirmation of recurrent tumor)
• Age 18-75 years old.
• Life expectancy of at least 12 weeks.
• Karnofsky performance status at least 60
• Participants must be able to adhere to the dosing and visit schedules, and agree to record medication times, concomitant medications, and adverse events (AEs) accurately and consistently in a daily diary.
• paraffinsections of glioblastoma tissue must be available.
• Participants must have normal organ and marrow function as defined below: leukocytes \>4.0×10\^9/L，platelets \>100×10\^9/L，Hemoglobin \> 10 g/dl，Serum creatinine\< 1.5-fold upper normal range，AST and ALT \<2-fold upper normal range, Alkaline phosphatase \< 3-fold upper normal range.
• Female and male subjects of childbearing potential must agree to use a medically accepted method of adequate contraception.

You may not qualify if:

• Treatment with any chemotherapy other than temozolomide prior to enrollment.
• Progressive or recurrent glioblastoma documented by MRI earlier than 12 weeks after completion of radiotherapy.
• History of any other cancer.
• HIV infection.
• Women who are pregnant or breast feeding.

Sponsors & Collaborators

• Beijing Sanbo Brain Hospital: lead

MeSH Terms

Conditions

Glioblastoma; Recurrence

Interventions

Temozolomide

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Dacarbazine; Triazenes; Organic Chemicals; Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Junping Zhang, MD

  Beijing Sanbo Brain Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Physician

Study Record Dates

• First Submitted: December 30, 2014
• First Posted: January 5, 2015
• Study Start: January 1, 2015
• Primary Completion: March 1, 2020
• Study Completion: September 1, 2020
• Last Updated: July 24, 2023

Record last verified: 2023-07